GlaxoSmithKline: GSK spends $19bn on US rival’s drugs to boost HIV battle
The drugs that GSK has bought still require approval by regulators
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The drugs giant GlaxoSmithKline tightened its grip on the $19bn market for HIV treatments yesterday by snapping up a selection of drugs from its rival Bristol-Myers Squibb.
The FTSE 100 outfit will pay $350m (£235m) upfront – and up to $1.1bn later, depending on sales – for two separate buckets of drugs that aim to treat HIV patients.
GSK’s majority-owned subsidiary Viiv Healthcare – a specialist HIV drugs business – struck the deal with the US-based Bristol-Myers Squibb.
GSK has had a longstanding role in HIV treatments, developing Zidovudine, the first-ever drug approved for use by American regulators. The treatment later became the focus of the Oscar-winning film Dallas Buyers Club.
Viiv’s chairman, David Redfern, said: “These acquisitions strengthen our leadership and innovation in HIV – one of our core areas of scientific research at GSK.”
The drugs that GSK has bought are in the latter stages of development and still require approval by regulators.
The most advanced of the drugs, Fostemsavir, is set to file for regulatory approval in the US in 2018.
Morgan Stanley analysts called it a “nice, complementary HIV research deal” and said the price paid was “reasonable”.
Viiv’s flagship product, Tivicay, has helped GSK close the gap on HIV market leader Gilead Sciences since the drug’s launch in 2013.
GSK’s chief executive. Sir Andrew Witty, had considered spinning out Viiv – founded in 2009 – into a standalone business on the stock market. But decided against the plan after investors urged the company to keep the unit because it was performing so well.
Viiv is 78 per cent owned by GSK – with the rest owned by its American competitor Pfizer and the Japanese pharmaceutical company Shionogi – and contributes around 10 per cent of GSK’s annual revenues. The division is the fastest growing in the group with compound growth of 10.3 per cent a year.
GSK’s HIV sales in the third quarter of this year were £622m – a 65 per cent increase year on year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments